Portfolio Building Block World Pharma and Biotech Index ETF
Data updated: 2026-09-21
C000265138 — Portfolio Building Block World Pharma and Biotech Index ETF. Holdings, fees, performance and SEC filings.
C000265138 Fund Overview
Portfolio Building Block World Pharma and Biotech Index ETF is a US ETF managed by Tidal Trust IV, categorised as United States Large Cap Blend / Core Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: Tidal Trust IV
- Category: United States Large Cap Blend / Core Health Care Equity
- Assets under management: $952.24M
- SEC CIK: 0002043390
- SEC series ID: S000096308
- Share class ID: C000265138
C000265138 Investment Objective and Strategy
Portfolio Building Block World Pharma and Biotech Index ETF describes its objective and strategy as follows, from its latest prospectus filed with the SEC by Tidal Trust IV.
Investment objective
The Portfolio Building Block World Pharma and Biotech Index ETF seeks to track the performance, before fees and expenses, of the BITA Global Pharma and Biotech Select Index (the Index).
Principal investment strategy
Overview The Fund uses a passive management (or indexing) approach to track the performance, before fees and expenses, of the Index. The Index is constructed using a rules-based methodology that identifies companies in the pharmaceutical and/or biotechnology industries with publicly traded ordinary shares listed on major stock exchanges in developed markets, as classified by BITA GmbH (the Index Provider). Index Overview: The Indexs initial universe consists of all publicly listed equity securities for which sufficient relevant information is available from public sources. The initial universe is screened using the following criteria, which are based on each companys financial information for the most recent quarter: A. Pharmaceutical or Biotechnology Industry : To be eligible for inclusion, a company must be classified as operating within either the pharmaceutical or biotechnology industry according to a rules-based methodology defined by the Index Provider.
This classification is determined by applying the following predefined criteria: According to BITAs thematic data methodology, to be eligible companies must have a Thematic Exposure Score of at least 50%. A companys total Thematic Exposure Score is equivalent to the sum of the revenue derived by the company from relevant products, services, and business activities (PSA), as a proportion of the companys total revenue. BITA approaches the construction and research of Themes through the mapping of PSA into a set of granular Sub-Themes designed to facilitate the construction of heavily focused index and data products. The universe includes companies whose PSA are integral to the biopharma ecosystem. These companies operate across the following Sub-Themes: ? Biotechnology-Based Therapeutics : Companies that develop, manufacture, or commercialize treatments based on genetic engineering, recombinant proteins, cell and gene therapies, or other biotech platforms.
This includes mRNA therapies, monoclonal antibodies, CRISPR-based editing, and personalized therapeutics. These firms are typically focused on treating complex or rare human diseases through biological innovation. ? Pharmaceutical Research & Manufacturing : Companies that are engaged in the discovery, development, and production of small-molecule drugs and traditional pharmaceuticals. This includes both branded and generic drug manufacturers, with operations spanning preclinical research, regulatory approval, and mass production. Veterinary medicine developers are also included. ? Precision Medicine & Genetic Diagnostics : Companies that focus on developing diagnostic tools and technologies used to guide individualized treatment decisions. This includes firms that offer genomic testing, biomarker-based diagnostics, companion diagnostics linked to specific therapies, and AI-enabled health insights aimed at improving treatment efficacy.
B. Market Capitalization : Companies with a market capitalization of at least $10 billion. C. Developed Markets : To be eligible for inclusion, a companys shares must be listed on a major stock exchange in a developed market. For the purposes of the Index, major stock exchanges in developed markets are defined as the following (listed alphabetically by country): Australia (Australian Stock Exchange); Austria (Wiener Borse); Belgium (Euronext Brussels); Canada (Canadian Securities Exchange, Toronto Stock Exchange, and TSX Venture Exchange); Denmark (Nasdaq Copenhagen); Finland (Nasdaq Helsinki); France (Euronext Paris Exchange); Germany (Deutsche Borse); Ireland (Euronext Irish Stock Exchange); Israel (Tel-Aviv Stock Exchange); Italy (Borsa Italiana); Japan (Tokyo Stock Exchange); Netherlands (Euronext Amsterdam); New Zealand (New Zealand Stock Exchange); Norway (Euronext Oslo Brs); Portugal (Euronext Lisbon); Singapore (Singapore Exchange); Spain (Bolsas y Mercados Espanoles); Sweden (Nasdaq Stockholm); Switzerland (SIX Swiss Exchange); United Kingdom (London Stock Exchange); and Unites States (Nasdaq and New York Stock Exchange).
D. Ordinary Shares : The Index includes only ordinary shares of eligible companies. Ordinary shares represent ownership in a company and typically give shareholders the right to vote and receive dividends. Companies that meet the foregoing screens are included in the Index. The Index is expected to be comprised of between 50 and 80 constituents, however, the number of constituents will vary over time. As of market close October 9, 2025, the Index contained 68 constituents. The Index is reconstituted and rebalanced quarterly (reconstitution means the Index is updated with new eligible companies based on current data; rebalancing means the weights of the companies in the Index are adjusted). In addition, the Index Provider may determine to substitute an Index constituent or make an extraordinary adjustment to the Index if it determines an extraordinary event has occurred.
The determination date for regular adjustments takes place on the first Friday of the rebalancing month. On each determination day, Index constituents are weighted according to their free-float market capitalization (i.e., the total market value of a companys shares that are readily available for public trading, excluding shares held by insiders or controlling shareholders). ). In addition, the Index methodology includes the following capping constraints to limit the amount that an issuer or issuers can make up of the Index: (1) no single issuer may exceed 25% of the Index weight; and (2) all issuers with individual weights above 4.5% may not, in the aggregate, exceed 45% of the total Index weight. To the extent the Index is concentrated in a particular industry or industries, the Fund is expected to be concentrated in that industry or industries.
It is expected that the Index will be concentrated in both the Pharmaceutical and Biotechnology industries or group of industries. The Index is owned, calculated, administered, and disseminated by the Index Provider. The Index Provider is not affiliated with the Funds investment adviser, Tidal Investments LLC (the Adviser). The Funds Investment Strategy Under normal circumstances, the Fund will invest at least 80% of the Funds net assets (plus borrowings for investment purposes) in component securities that make up the Index. The Fund attempts to invest all, or substantially all, of its assets in the component securities that make up the Index. The Fund will generally use a replication strategy to achieve its investment objective, meaning it generally will invest in all of the component securities of the Index.
However, the Fund may use a representative sampling strategy, meaning it may invest in a sample of the securities in the Index whose risk, return and other characteristics closely resemble the risk, return and other characteristics of the Index as a whole, when the Adviser believes it is in the best interests of the Fund. For example, representative sampling may be used when replicating the Index involves practical difficulties or substantial costs, an Index constituent becomes temporarily illiquid, unavailable, or less liquid, or as a result of legal restrictions or limitations that apply to the Fund but not to the Index. The Fund will invest in listed equity securities, which may include common stocks, business trust shares, American Depositary Receipts (ADRs), which are securities listed on US exchanges that represent shares of foreign companies, and other equity investments or ownership interests in business enterprises.
Under normal market conditions, the Fund will invest at least 40% (unless the portfolio managers deem market conditions unfavorable, in which case the Fund would invest at least 30%) of its assets in securities of issuers located outside the United States. The Fund will allocate its assets among different countries (one of which may be the United States). The Fund is classified as non-diversified, which means the Fund may invest a larger percentage of its assets in the securities of a smaller number of issuers than a diversified fund.
C000265138 Holdings
Top 10 holdings of Portfolio Building Block World Pharma and Biotech Index ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Eli Lilly & Company | 15.20% |
| Johnson & Johnson | 9.66% |
| Abbvie, Inc. | 6.94% |
| Roche Holding AG | 5.05% |
| Merck & Company, Inc. | 5.04% |
| Amgen, Inc. | 4.64% |
| Novartis AG | 4.47% |
| Astrazeneca PLC | 3.90% |
| Gilead Sciences, Inc. | 3.77% |
| Novo Nordisk A/s | 3.51% |
C000265138 Portfolio Allocation
Asset-class allocation of Portfolio Building Block World Pharma and Biotech Index ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.5% |
| Cash & Equivalents | 0.3% |
C000265138 Performance
Total returns for C000265138 (as of 2026-10-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 3.5% |
C000265138 Costs and Fees
C000265138 costs about $13 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.13%
- Gross expense ratio: 0.13%
C000265138 Cashflows
Over the 12 months to 2026-01, Portfolio Building Block World Pharma and Biotech Index ETF had net inflows of $35.60M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-01 | $34.62M |
| 2025-12 | $0 |
| 2025-11 | $986.39K |
C000265138 Debt Constituents
No individual debt constituents are reported in Portfolio Building Block World Pharma and Biotech Index ETF's latest SEC N-PORT filing.
C000265138 Prospectus and SEC Filings
Official Portfolio Building Block World Pharma and Biotech Index ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Large Cap Blend / Core Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.